



ATTORNEYS AT LAW



Robert Greene Sterne  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffens  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Homer  
Robert C. Millonig  
Donald J. Featherstone  
Timothy J. Shea, Jr  
Michael V. Messinger  
Judith U. Kim

Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Eldora L. Ellison  
Thomas C. Flata  
Donald R. Banowitz  
Peter A. Jackman  
Jeffrey S. Weaver  
Brian J. Del Buono  
Vincent L. Capuano  
Virgil Lee Beaston  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Rae Lynn P. Guest  
Daniel A. Klein  
Jason D. Eisenberg

Michael D. Specht  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longsworth  
Lori A. Gordon  
Ted J. Ebersole  
Laura A. Vogel  
Bryan S. Wade  
Bashir M.S. Ali  
Shannon A. Carroll  
Matthew E. Kelley  
Michelle K. Holoubek  
Marsha A. Rose\*

W. Blake Coblenz\*  
James J. Pohl\*  
John T. Haran\*  
Mark W. Rygiel  
**Registered Patent Agents**  
Karen R. Markowicz  
Matthew J. Dowd  
Katrina Yujian Pei Quach  
Bryan L. Skeeton  
Robert A. Schwartzman  
Teresa A. Colella  
Victoria S. Rutherford  
Simon J. Elliott  
Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse  
Christopher J. Walsh

Liliana Di Nola-Baron  
Peter A. Socarnas  
Jeffrey Mills  
Danielle L. Letting  
Lori Brandes

**Of Counsel**  
Edward J. Kessler  
Kenneth C. Bass III  
Marvin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

February 21, 2006

**WRITER'S DIRECT NUMBER:**  
(202) 772-8560

**INTERNET ADDRESS:**  
RESMOND@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Art Unit 1616**

**Attn: Mail Stop Amendment**

Re: U.S. Utility Patent Application  
Application No. 10/826,923; Filed: April 19, 2004  
For: **Methods of Treating Diseases Responsive to Induction of Apoptosis  
and Screening Assays**  
Inventors: Kasibhatla *et al.*  
Our Ref: 1735.0870001/RWE/BSA

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b);
2. Two (2) pages of Form PTO-1449 citing three (3) documents;
3. A copy of each of the three (3) cited documents (AS1, AT1 and AR2); and
4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
February 21, 2006  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

RWE/BSA/nef  
Enclosures

496179\_1.DOC



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kasibhatla *et al.*

Appl. No.: 10/826,923

Filed: April 19, 2004

For: **Methods of Treating Diseases  
Responsive to Induction of  
Apoptosis and Screening Assays**

Confirmation No.: 1333

Art Unit: 1616

Examiner: *To Be Assigned*

Atty. Docket: 1735.0870001/RWE/BSA

**First Supplemental Information Disclosure Statement  
Filing Under 37 C.F.R. § 1.97(b)**

***Mail Stop Amendment***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on July 19, 2005 in connection with the above-captioned application. Copies of the documents are submitted herewith.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893


Date: 2.21.06

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

495734\_1.DOC

FORM PTO-1449

FIRST SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1735.0870001/RWE/BSAAPPLICATION NO.  
10/826,923APPLICANT(S)  
Kasibhatla, S., et al.FILING DATE  
April 19, 2004GROUP  
1616

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI9						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS	1	Ganley, I.G., et al., "Rab9 GTPase Regulates Late Endosome Size and Requires Effector Interaction for Its Stability," <i>Mol. Biol. Cell.</i> 15:5420-5430, The American Society for Cell Biology (December 2004)
	AT	1	International Search Report for International Application No. PCT/US04/11916, ISA, Alexandria, VA, mailed December 13, 2005

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449		ATTY. DOCKET NO. 1735.0870001/RWE/BSA	APPLICATION NO. 10/826,923
<u>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>		APPLICANT(S) Kasibhatla, S., et al.	
		FILING DATE April 19, 2004	GROUP 1616

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI9						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	2	Zhang, H.-Z., et al., "Discovery and Structure-Activity Relationship of 3-Aryl-5-aryl-1,2,4-oxadiazoles as a New Series of Apoptosis Inducers and Potential Anticancer Agents," J. Med. Chem. 48:5215-5223, American Chemical Society (Published online July 2005)				
	AS						
	AT						
EXAMINER						DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							